When: 23-26 April 2012

Where: Grand Hyatt, Shanghai, China

Conference Summary:

With a market opportunity worth US$80bn of biologics coming off patent by 2020, it is not a small sum the pharmaceutical industry can risk ignoring. To top it off, the extended global financial crisis has increased pressure on the regulators and the pharma industry to find a solution for more affordable and accessible drugs.

IBC’s 3^rd Annual Biosimilars Asia 2012 is the largest and most anticipated meeting of its kind in Asia. Attended by biosimilars, innovators, generics and biopharma alike, the unique mix of attendees from all over the world will share their experiences and opinions about the future of biosimilars. Tough questions will be answered and positions will be challenged but all will walk away bristling with ideas, opportunities and be more informed. Biosimilars Asia 2012 will deliver a quality of speakers and discussions unmatched in Asia.By one estimate, $25 bil. in biologics will go off-patent by 2016, and potential biosimilars sales in 2014 could reach $19.4 bil., with EPO products the largest slice at $6.1 bil. The push to market biosimilars is well on its way.

Speakers Include:

-         Rich DiCicco, Chairman, Harvest Moon Pharmaceuticals (Conference Chair)

-         Alan Sheppard, Principal, Global Generics, Thought Leadership, IMS (UK)

-         David Shen, Global Head of Biologics Research and Early Development, Teva (US)

-         Tadashi Matsumoto, President, ReqMed (Japan)

-         Tong Zhang, Director, Pan Regional Lead, Emerging Market Business Development, MSD (US)

-         Joe Zhou, CEO, Wison (China)

-         Youling Wu, CEO, ZheJiang Teruisi (China)

-         Song Jun, BD Manager, Strategy & Business Development, Pfizer (China)

-         Stanley Hong, SVP R&D,  Celltrion (Korea)

-         Kyu Don Kim, VP Strategic BD, Samsung (Korea)

-         Abdullah Baaj, CEO, Boston Oncology (Syria)

-         Dr. Subir Basak, Chief Commercial Officer, Intas Biopharmaceuticals (India)

-         Suzette Kox, Senior Director Scientific Affairs, European Generic Medicines Association (EGA) (UK)

-         Dr Yingfei Wei, CEO, Elixirin Corporation (USA)

-         Shirley Zhao, General Manager, Genzyme (China)

-         Dr Ming Wang, Executive Director and Head of Diabetes Research, Amgen (USA)

-         Dr Arthur Alston, International Business Leader, Biosimilars, Roche (Switzerland)

-         Julie Seawall, Executive Director, Corporate Development, Merck Bioventures (USA)

Schedule:
Some of the following topics over the course of 2 days include:
-External Collaborations & Commercial Valuation
-Mad about mAbs
-Developing Biosimilars & Biobetters
-Winning Buy-in
-Closing Panel Debate